Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02485717 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies
A Phase 3 study, sponsored by ParaPRO.
- Completed
- Registry status
- Phase 3
- Development phase
- 291
- Enrollment target
NCT02485717 is a Phase 3 study that has completed, run by ParaPRO. The registered enrollment target is 291 participants.
The verdict
NCT02485717, a Phase 3 study, has completed, sponsored by ParaPRO.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 291 participants
- Enrollment target
Study Summary
To assess the safety and efficacy of Natroba (spinosad) topical suspension versus placebo for the clinical cure of scabies after a single treatment. The trial will also assess the pharmacokinetics (PK) of spinosad and benzyl alcohol following a single dose of Natroba™ in pediatric subjects 4-16 years of age. These subjects will be a separate population of pediatric subjects.
Interventions
- OTHER Placebo
- DRUG spinosad topical suspension, 0.9%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 291 participants |
| Start Date | 2017-05-02 |
| Est. Completion | 2018-06-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02485717
The ClinicalTrials.gov registry entry for NCT02485717 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 291 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ParaPRO, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02485717 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02485717 about?
NCT02485717 is a clinical study titled "Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies". To assess the safety and efficacy of Natroba (spinosad) topical suspension versus placebo for the clinical cure of scabies after a single treatment. The trial will also assess the pharmacokinetics (PK) of spinosad and benzyl alcohol following a single dose of Natroba™ in pediatric subjects 4-16 year...
What is the current status of trial NCT02485717?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 291 participants. The study started on 2017-05-02. Estimated completion is 2018-06-25.
What interventions are being tested in trial NCT02485717?
The interventions under investigation include: Placebo (OTHER), spinosad topical suspension, 0.9% (DRUG).
Who is sponsoring clinical trial NCT02485717?
This trial is sponsored by ParaPRO, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.